The U.S. Food and Drug Administration said on Friday it had approved Eli Lilly and Co’s migraine drug, Reyvow. The drug has been approved to treat acute migraine with or without aura, a sensory phenomenon or visual disturbance, in adults. Lilly acquired Reyvow, formerly called lasmiditan, in a deal https://www.reuters.com/article/us-colucid-pharms-m-a-eli-lilly-idUSKBN1521O6 worth about $960 million when it bought CoLucid Pharmaceuticals Inc in early 2017. …read more
Source:: Yahoo Finance
